CVRx, Inc. (NASDAQ:CVRX) Stock Rated “Hold” by Sell-Side Analysts

CVRx, Inc. (NASDAQ:CVRX – Get Free Report) has received an average recommendation of “Hold” from the seven analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $3.30.

Several equities research analysts recently commented on the stock. Piper Sandler lowered shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research note on Friday, August 7th. Craig Hallum cut CVRx from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research report on Friday, August 7th. William Blair downgraded shares of CVRx from an “outperform” rating to a “market perform” rating in a research report on Friday, November 6th. Wall Street Zen downgraded CVRx from a “sell” rating to a “strong sell” rating in a research note on Sunday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a report on Friday, October 30th.

Get Our Latest Stock Report on CVRX

CVRx Trading Down 3.6%

Shares of CVRX traded down $0.02 during trading hours on Friday, reaching $0.61. 759,885 shares of the company traded hands, compared to its average volume of 800,013. The company’s fifty day moving average price is $1.85 and its two-hundred day moving average price is $5.00. The company has a quick ratio of 5.71, a current ratio of 6.80 and a debt-to-equity ratio of 4.24. The company has a market capitalization of $17.30 million, a price-to-earnings ratio of -0.30 and a beta of 0.81. CVRx has a 12 month low of $0.60 and a 12 month high of $10.28.

CVRx (NASDAQ:CVRX – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The firm had revenue of $13.83 million for the quarter, compared to analysts’ expectations of $13.93 million. CVRx had a negative return on equity of 208.45% and a negative net margin of 88.28%. Equities research analysts predict that CVRx will post -2.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CVRX. Deutsche Bank AG purchased a new position in CVRx in the 2nd quarter worth approximately $62,000. Renaissance Technologies LLC purchased a new position in CVRx during the 1st quarter valued at approximately $183,000. Bank of America Corp DE purchased a new position in CVRx during the 2nd quarter valued at approximately $102,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in CVRx during the 2nd quarter valued at approximately $107,000. Finally, Empowered Funds LLC bought a new stake in CVRx in the 3rd quarter worth approximately $63,000. Hedge funds and other institutional investors own 75.27% of the company’s stock.

Key Stories Impacting CVRx

These are some of the CVRX stories that stood out recently:

  • Negative Sentiment: Investors allege CVRx misled shareholders during July 25, 2023–August 6, 2026, including about alleged conduct that could expose the company to liability under the False Claims Act and Anti-Kickback Statute. The complaints cite a DOJ Civil Investigative Demand, sharp revenue-guidance reductions, disruption to the commercial sales force, and the departure of the chief revenue officer. These remain allegations, not proven findings; continued litigation could bring costs and uncertainty. Securities fraud lawsuit report Hagens Berman class-action notice
  • Neutral Sentiment: Law firms are publicizing the case and urging eligible investors to seek appointment as lead plaintiff by January 8, 2027. These repeated notices largely concern the same lawsuit rather than separate new cases or company operating updates. Lead plaintiff deadline notice

About CVRx

(Get Free Report)

CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.

Further Reading

Analyst Recommendations for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.